{"id":1807,"date":"2005-10-01T01:00:00","date_gmt":"2005-10-01T00:00:00","guid":{"rendered":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/"},"modified":"2018-10-20T18:39:40","modified_gmt":"2018-10-20T16:39:40","slug":"prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc","status":"publish","type":"post","link":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/","title":{"rendered":"PRISE EN CHARGE DES MALADES CO-INFECTES  VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC."},"content":{"rendered":"<p><strong>2005<\/strong><\/p>\n<p><em>Isabelle Rosa, Alice Yap, Val\u00e9rie Garrait, Isabelle de Lacroix, Brigitte Elharrar, Violaine Ozenne, Ga\u00eblle Pileire, Thierry Lons, Herv\u00e9 Hag\u00e8ge, Michel Chousterman.<br \/>\nService d&rsquo;H\u00e9pato-Gastroent\u00e9rologie et de M\u00e9decine Interne, CHI de Cr\u00e9teil<\/em><\/p>\n<p><strong>H\u00e9patologie <\/strong>&#8211; \u00a02005-08-26 &#8211;\u00a0COS &#8211;<\/p>\n<p>________________________________<\/p>\n<p>Le traitement de l\u2019h\u00e9patite C chez les malades co-infect\u00e9s VIH-VHC est devenu une priorit\u00e9 du fait d\u2019une augmentation de la morbidit\u00e9 et de la mortalit\u00e9 li\u00e9e \u00e0 l\u2019h\u00e9patite C chez ces malades. Le but de ce travail \u00e9tait d\u2019\u00e9valuer les r\u00e9sultats du traitement de l\u2019h\u00e9patite C chez des malades co-infect\u00e9s b\u00e9n\u00e9ficiant d\u2019une prise en charge pluridisciplinaire par une double \u00e9quipe d\u2019infectiologues et d\u2019h\u00e9patologues, au sein d\u2019une m\u00eame service, en h\u00f4pital g\u00e9n\u00e9ral.<br \/>\nMalades et m\u00e9thodes : Il s\u2019agissait d\u2019une \u00e9tude r\u00e9trospective conduite d\u2019octobre 2000 \u00e0 mai 2005. 442 malades \u00e9taient suivis pour une infection par le VIH et 73 (16%) \u00e9taient co-infect\u00e9s par le VHC. Parmi ces malades, 60 (82 %) ont eu une \u00ab prise en charge h\u00e9patologique \u00bb. Trente malades n&rsquo;ont pas \u00e9t\u00e9 trait\u00e9s (8 refus, 7 contre-indications psychiatriques, 8 absences d&rsquo;indication h\u00e9patique (5 scores F0\/F1, 3 PCR C n\u00e9gatives) et 7 contre-indications li\u00e9es au VIH ou g\u00e9n\u00e9rale). Parmi les 30 malades trait\u00e9s, 23 malades ont achev\u00e9 leur traitement antiviral C \u00e0 la fin de l&rsquo;\u00e9tude et 7 sont en cours de traitement.  Les caract\u00e9ristiques des malades trait\u00e9s \u00e9taient les suivantes: hommes 54 % ; \u00e2ge 44 \u00b1 8 ans; mode de contamination des deux virus: toxicomanie intraveineuse 68 %, h\u00e9t\u00e9rosexuelle 18 % et transfusion 14%. 50 % des malades \u00e9taient au stade C selon la classification CDC d\u2019Atlanta (CD4 : 515 \u00b1 239 \/mm3; charge virale VIH moyenne: 10 800 copies\/ml). Les malades \u00e9taient trait\u00e9s par trith\u00e9rapie dans 20 cas, par bith\u00e9rapie dans 2 cas et 1 malade n\u2019avait pas de traitement anti-r\u00e9troviral. Concernant l&rsquo;h\u00e9patite C, les  malades \u00e9taient infect\u00e9s par un g\u00e9notype 1, 2, 3 et 4 dans respectivement 15, 2, 3 et 3 cas. 64 % des malades avaient une charge virale C &gt; 850 000 UI\/ml. Une biopsie h\u00e9patique avait \u00e9t\u00e9 r\u00e9alis\u00e9e chez 21 malades sur 23. Selon Metavir, le score moyen d\u2019activit\u00e9 \u00e9tait de 2 et le score de fibrose moyen \u00e9tait de 3. Sept malades (33%)  avaient une cirrhose. Les malades ont tous re\u00e7us de l\u2019Interf\u00e9ron pegyl\u00e9 en association \u00e0 la Ribavirine \u00e0 des doses allant de 800 \u00e0 1200 mg par jour. La dur\u00e9e moyenne de traitement \u00e9tait de 7,8 mois.<br \/>\nR\u00e9sultats : Une r\u00e9ponse virologique prolong\u00e9e a \u00e9t\u00e9 observ\u00e9e chez 5\/23 (22 %) malades. Le traitement a d\u00fb \u00eatre arr\u00eat\u00e9 en raison d\u2019une non r\u00e9ponse dans 7 cas et de fa\u00e7on pr\u00e9matur\u00e9e dans 5 cas (4 d\u00e9pressions ou d\u00e9compensations d\u2019une psychose et 1 toxidermie). Une an\u00e9mie avec h\u00e9moglobin\u00e9mie inf\u00e9rieure \u00e0 10 g\/dl est survenue chez 5 malades et un traitement par \u00e9rythropo\u00efetine a \u00e9t\u00e9 instaur\u00e9 chez 4 d\u2019entre eux. Chez un malade, un traitement par facteurs de croissance a \u00e9t\u00e9 d\u00e9but\u00e9 en raison d&rsquo;une neutrop\u00e9nie &lt;500\/mm3. La perte de poids \u00e9tait de 3 \u00b1 2,6 kg en moyenne. Deux malades ont eu une \u00e9l\u00e9vation isol\u00e9e des lactates sans autre signe en faveur d\u2019une cytopathie mitochondriale. Aucune complication li\u00e9e au VIH n\u2019est survenue en cours de traitement.<br \/>\nConclusion : Parmi les malades co-infect\u00e9s par le VIH-VHC suivis dans notre h\u00f4pital, 60% des malades ont pu \u00eatre trait\u00e9s, avec un taux de r\u00e9ponse virologique prolong\u00e9e de 22%. Vingt pour cent des malades ont arr\u00eat\u00e9 leur traitement pour effet ind\u00e9sirable. Dans notre exp\u00e9rience, une prise en charge pluri-disciplinaire favorise l&#039;acc\u00e8s au traitement de ces malades.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2005 Isabelle Rosa, Alice Yap, Val\u00e9rie Garrait, Isabelle de Lacroix, Brigitte Elharrar, Violaine Ozenne, Ga\u00eblle Pileire, Thierry Lons, Herv\u00e9 Hag\u00e8ge, Michel Chousterman. Service d&rsquo;H\u00e9pato-Gastroent\u00e9rologie et de M\u00e9decine Interne, CHI de Cr\u00e9teil H\u00e9patologie &#8211; \u00a02005-08-26 &#8211;\u00a0COS &#8211; ________________________________ Le traitement de l\u2019h\u00e9patite C chez les malades co-infect\u00e9s VIH-VHC est devenu une priorit\u00e9 du fait d\u2019une augmentation [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[3],"tags":[16],"class_list":["post-1807","post","type-post","status-publish","format-standard","hentry","category-hepatologie","tag-16"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC. - Abstracts des congr\u00e8s de l&#039;ANGH<\/title>\n<meta name=\"description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC. - Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"og:description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/\" \/>\n<meta property=\"og:site_name\" content=\"Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\" \/>\n<meta property=\"article:published_time\" content=\"2005-10-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-10-20T16:39:40+00:00\" \/>\n<meta name=\"author\" content=\"abstracts\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"abstracts\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/\"},\"author\":{\"name\":\"abstracts\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\"},\"headline\":\"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC.\",\"datePublished\":\"2005-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:39:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/\"},\"wordCount\":619,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"keywords\":[\"2005\"],\"articleSection\":[\"Hepatologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/\",\"url\":\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/\",\"name\":\"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC. - Abstracts des congr\u00e8s de l&#039;ANGH\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#website\"},\"datePublished\":\"2005-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:39:40+00:00\",\"description\":\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\",\"breadcrumb\":{\"@id\":\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/angh.net\/abstracts\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/angh.net\/abstracts\/#website\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"name\":\"Abstracts des congr\u00e8s de l&#039;ANGH\",\"description\":\"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003\",\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/angh.net\/abstracts\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\",\"name\":\"ANGH\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"contentUrl\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"width\":48,\"height\":18,\"caption\":\"ANGH\"},\"image\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\",\"name\":\"abstracts\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"caption\":\"abstracts\"},\"url\":\"https:\/\/angh.net\/abstracts\/author\/abstracts\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC. - Abstracts des congr\u00e8s de l&#039;ANGH","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/","og_locale":"fr_FR","og_type":"article","og_title":"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC. - Abstracts des congr\u00e8s de l&#039;ANGH","og_description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","og_url":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/","og_site_name":"Abstracts des congr\u00e8s de l&#039;ANGH","article_publisher":"https:\/\/www.facebook.com\/ANGH-2136322560030484\/","article_published_time":"2005-10-01T00:00:00+00:00","article_modified_time":"2018-10-20T16:39:40+00:00","author":"abstracts","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"abstracts","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/#article","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/"},"author":{"name":"abstracts","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1"},"headline":"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC.","datePublished":"2005-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:39:40+00:00","mainEntityOfPage":{"@id":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/"},"wordCount":619,"commentCount":0,"publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"keywords":["2005"],"articleSection":["Hepatologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/","url":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/","name":"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC. - Abstracts des congr\u00e8s de l&#039;ANGH","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/#website"},"datePublished":"2005-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:39:40+00:00","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","breadcrumb":{"@id":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/angh.net\/abstracts\/prise-en-charge-des-malades-co-infectes-vih-vhc-en-hopital-general-resultats-du-traitement-anti-vhc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/angh.net\/abstracts\/"},{"@type":"ListItem","position":2,"name":"PRISE EN CHARGE DES MALADES CO-INFECTES VIH-VHC EN HOPITAL GENERAL : RESULTATS DU TRAITEMENT ANTI-VHC."}]},{"@type":"WebSite","@id":"https:\/\/angh.net\/abstracts\/#website","url":"https:\/\/angh.net\/abstracts\/","name":"Abstracts des congr\u00e8s de l&#039;ANGH","description":"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003","publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angh.net\/abstracts\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/angh.net\/abstracts\/#organization","name":"ANGH","url":"https:\/\/angh.net\/abstracts\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/","url":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","contentUrl":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","width":48,"height":18,"caption":"ANGH"},"image":{"@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ANGH-2136322560030484\/"]},{"@type":"Person","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1","name":"abstracts","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","caption":"abstracts"},"url":"https:\/\/angh.net\/abstracts\/author\/abstracts\/"}]}},"_links":{"self":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/comments?post=1807"}],"version-history":[{"count":0,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1807\/revisions"}],"wp:attachment":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/media?parent=1807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/categories?post=1807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/tags?post=1807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}